[go: up one dir, main page]

PE20090320A1 - Derivados de piperidina-amida - Google Patents

Derivados de piperidina-amida

Info

Publication number
PE20090320A1
PE20090320A1 PE2008000919A PE2008000919A PE20090320A1 PE 20090320 A1 PE20090320 A1 PE 20090320A1 PE 2008000919 A PE2008000919 A PE 2008000919A PE 2008000919 A PE2008000919 A PE 2008000919A PE 20090320 A1 PE20090320 A1 PE 20090320A1
Authority
PE
Peru
Prior art keywords
benzo
piperidine
amide derivatives
tiazol
ilo
Prior art date
Application number
PE2008000919A
Other languages
English (en)
Inventor
Mirjana Andjelkovic
Simona M Ceccarelli
Odile Chomienne
Patrizio Mattei
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20090320A1 publication Critical patent/PE20090320A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

REFERIDA A COMPUESTOS DE FORMULA I, EN LA QUE X ES S E Y ES CR3 O X ES CR3 E Y ES S; R1 ES FENILO, NAFTILO, PIRIDINILO, BENZO[1,3]DIOXOL-5-ILO, ENTRE OTROS; R2 ES 1,3-DIHIDROINDOLIL-2-ONA, 2,3-DIHIDRO-BENZO[1,4]DIOXINILO, BENZO[1,3]DIOXOL-5-ILO, ENTRE OTROS; R3 ES H, HALOGENO, CN, ENTRE OTROS. SON SELECCIONADOS: 1-{(R)-2-[4-(4-CLORO-FENIL)-TIAZOL-2-IL]-PIPERIDIN-1-IL}-2-FENOXI-ETANONA, 3-{2-[(R)-1-(2-FENOXI-ACETIL)-PIPERIDIN-2-IL]-TIAZOL-4-IL}-BENZOATO SODICO, ENTRE OTROS. REFERIDA TAMBIEN A UN PROCESO DE PREPARACION Y COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA L-CPT1, UTILES EN EL TRATAMIENTO DE DIABETES Y PATOLOGIAS ASOCIADAS
PE2008000919A 2007-06-01 2008-05-29 Derivados de piperidina-amida PE20090320A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07109458 2007-06-01

Publications (1)

Publication Number Publication Date
PE20090320A1 true PE20090320A1 (es) 2009-03-19

Family

ID=39645621

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000919A PE20090320A1 (es) 2007-06-01 2008-05-29 Derivados de piperidina-amida

Country Status (17)

Country Link
US (1) US8039487B2 (es)
EP (1) EP2155738B1 (es)
JP (1) JP5220848B2 (es)
KR (1) KR101140520B1 (es)
CN (1) CN101679404B (es)
AR (1) AR066759A1 (es)
AT (1) ATE518857T1 (es)
AU (1) AU2008257693B2 (es)
BR (1) BRPI0811978A2 (es)
CA (1) CA2689383C (es)
CL (1) CL2008001552A1 (es)
ES (1) ES2369315T3 (es)
IL (1) IL202159A (es)
MX (1) MX2009013003A (es)
PE (1) PE20090320A1 (es)
TW (1) TW200901997A (es)
WO (1) WO2008145596A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2736177A1 (en) * 2007-09-06 2009-03-12 Boston Biomedical, Inc. Compositions of kinase inhibitors and their use for treatment of cancer and other diseases related to kinases
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2014057435A1 (en) 2012-10-10 2014-04-17 Actelion Pharmaceuticals Ltd Orexin receptor antagonists which are [ortho bi (hetero )aryl]-[2-(meta bi (hetero )aryl)-pyrrolidin-1-yl]-methanone derivatives
EP3039022A4 (en) * 2013-08-29 2017-08-16 Baylor College Of Medicine Compositions and methods for the treatment of metabolic and body weight related disorders
EP4334313A1 (en) * 2021-05-04 2024-03-13 2N Pharma ApS Diazepane derivatives, processes for their preparation, and uses thereof for the amelioration, prevention and/or treatment of mental and neurological diseases
WO2023285349A1 (en) * 2021-07-12 2023-01-19 2N Pharma Aps Carnitine-palmitoyl-transferase-1 (cpt-1) inhibitors for use in a method of preventing or treating sepsis in a mammalian subject

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1165519A1 (en) * 1999-04-02 2002-01-02 Neurogen Corporation Aryl and heteroaryl fused aminoalkyl-imidazole derivatives and their use as antidiabetics
FR2865733B1 (fr) * 2004-02-04 2007-10-12 Merck Sante Sas Derives de thiazolylimidazole, leurs procedes de preparation, les compositions pharmaceutiques qui les contiennent et leurs applications en medecine
EP1604989A1 (en) * 2004-06-08 2005-12-14 Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft DPP-IV inhibitors
CA2608837C (en) * 2005-06-06 2011-08-02 F. Hoffmann-La Roche Ag Sulfonamide derivatives useful as liver carnitine palmitoyl transferase (l-cpt1) inhibitors
AU2006290803B2 (en) * 2005-09-15 2009-11-26 F. Hoffmann-La Roche Ag Novel heterobicyclic derivatives useful as inhibitors of liver carnitine palmitoyl transferase
PT1959951E (pt) * 2005-12-01 2010-03-02 Hoffmann La Roche Derivados de piperidina substituídos com heteroarilo, como inibidores de pct1-f
EP2271405B1 (en) * 2008-05-05 2013-07-24 Merck Patent GmbH Nip thiazole derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1
DE102008029734A1 (de) * 2008-06-23 2009-12-24 Merck Patent Gmbh Thiazolyl-piperidinderivate

Also Published As

Publication number Publication date
KR20100017976A (ko) 2010-02-16
ATE518857T1 (de) 2011-08-15
IL202159A0 (en) 2010-06-16
KR101140520B1 (ko) 2012-04-30
AU2008257693A1 (en) 2008-12-04
BRPI0811978A2 (pt) 2014-11-18
TW200901997A (en) 2009-01-16
JP5220848B2 (ja) 2013-06-26
EP2155738A1 (en) 2010-02-24
IL202159A (en) 2013-07-31
EP2155738B1 (en) 2011-08-03
CL2008001552A1 (es) 2009-05-22
WO2008145596A1 (en) 2008-12-04
MX2009013003A (es) 2010-01-20
CA2689383A1 (en) 2008-12-04
ES2369315T3 (es) 2011-11-29
CA2689383C (en) 2013-10-08
AR066759A1 (es) 2009-09-09
US8039487B2 (en) 2011-10-18
US20080300279A1 (en) 2008-12-04
CN101679404B (zh) 2012-06-13
AU2008257693B2 (en) 2011-01-27
JP2010529001A (ja) 2010-08-26
CN101679404A (zh) 2010-03-24

Similar Documents

Publication Publication Date Title
NO20084853L (no) Forbindelser som er agonister av muscarinreseptorer og som kan vaere effektive i behandling av smerte, Alzheimers sykdom og/eller schizofreni
PE20081238A1 (es) Piperidinas sustituidas como antagonistas de hdm2
PE20081845A1 (es) Nuevos derivados de aminopirimidina como inhibidores de plk1
PE20091689A1 (es) DERIVADOS DE 4-AMINOCICLOHEXANO SUSTITUIDO CON ACTIVIDAD SOBRE RECEPTORES µ Y ORL-1
PE20081532A1 (es) Compuestos novedosos
PE20080944A1 (es) Derivados de pirimidina como inhibidores del receptor de cinasa activina(alk-5)
PE20051173A1 (es) Compuestos azabiciclico (3.1.0) hexanos como moduladores de receptores de dopamina d3
PE20080056A1 (es) Derivados de cromencarboxamida como antagonistas del receptor s1p1
HRP20090340T1 (hr) Derivati 5-fenil-4-metil-tiazol-2-il-amina kao inhibitori enzima fosfatidilinozitol 3-kinaza (pi3) za liječenje upalnih bolesti dišnih puteva
NO20091596L (no) Benzoylamino-heterocykliske forbindelser som Glucokinase-(GLK)-activatorer
PE20090320A1 (es) Derivados de piperidina-amida
PE20091527A1 (es) Derivados de piridazinona
PE20050874A1 (es) Compuestos de bencimidazolona que tienen actividad agonista del receptor 5-ht4
PE20110136A1 (es) Compuestos organicos
PE20121050A1 (es) Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog
PE20091173A1 (es) Derivados de heteroarilo como antagonistas de receptor de orexina
BRPI0911035A2 (pt) ativadores de pirrolidinona glicoquinase
PE20141375A1 (es) Activadores de glucoquinasa
MX2010002584A (es) Derivados de piperidina como agonistas de receptores muscarinicos.
PE20110433A1 (es) Antagonistas de la via hedgehog de ftalazina disustituida
NZ596154A (en) Cyclic compound having substituted phenyl group
PE20091649A1 (es) Derivados de pirrolidinilo
PE20080094A1 (es) COMPUESTOS DE DIALQUILFENILO CON ACTIVIDAD AGONISTA DEL RECEPTOR ß2 ADRENERGICO Y ANTAGONISTA DEL RECEPTOR MUSCARINICO
CL2009000256A1 (es) Imidazolinas fenil sustituidas, composicion farmaceutica que contenga estos compuestos y su uso en el sindrome metabolico, obesidad, diabetes, sindrome de stein-leventhal, transtornos del snc, esquizofrenia, alzheimer, dependencia al alcohol y dependencia a la nicotina.
PE20060298A1 (es) Derivados de acido carboxilico de bencimidazolona

Legal Events

Date Code Title Description
FD Application declared void or lapsed